Arvinas Inc
Arvinas Inc (ARVN) Covered Calls
As of September 23, 2026, ARVN has 10 covered call opportunities in the coming three months. Return ranges from 10.5 to 46.9% until expiration. Annualized return ranges from 18.9 to 275.2%. The nearest expiration is October 16, 2026. Maximum potential profit is $399.
Read more
Running ARVN covered calls helps you generate consistent income from Arvinas Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Arvinas Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best ARVN covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if ARVN stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling ARVN covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Arvinas Inc covered call is worth writing.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Income-focused investors, long-term ARVN holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling ARVN covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Arvinas Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile15.48% Subdued
- Market cap (M$)512
- 52 weeks high-46.04%
- 52 weeks low12.34%
- Analyst recommendationBuy
2.31 - Target price$13.93
79.74% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-04
- P/E48.82
- Future P/E—
- EPS (ttm)0.16
- EPS growth next 5 years—
As of September 23, 2026
| 2026-10-16 | 24 | 10.00 | 17.51 | 0.05 | 0.15 | 154.00 | 18.10 | 275.22 | -0.59 | +0.16 | 262 | 0.10 |
| 2026-11-20 | 59 | 10.00 | 17.51 | 0.10 | 0.45 | 159.00 | 18.68 | 115.59 | -1.18 | +0.27 | 0 | 0.35 |
| 2027-01-15 | 115 | 11.00 | 29.26 | 0.15 | 0.70 | 264.00 | 31.02 | 98.46 | -1.76 | +0.28 | 91 | 0.55 |
| 2027-04-16 | 206 | 12.00 | 41.01 | 0.20 | 1.15 | 369.00 | 43.36 | 76.83 | -2.35 | +0.33 | 0 | 0.95 |
| 2027-01-15 | 115 | 10.00 | 17.51 | 0.40 | 1.55 | 189.00 | 22.21 | 70.49 | -4.70 | +0.45 | 351 | 1.15 |
| 2026-11-20 | 59 | 9.00 | 5.76 | 0.40 | 0.75 | 89.00 | 10.46 | 64.70 | -4.70 | +0.46 | 0 | 0.35 |
| 2027-04-16 | 206 | 10.00 | 17.51 | 0.60 | 2.15 | 209.00 | 24.56 | 43.52 | -7.05 | +0.51 | 0 | 1.55 |
| 2028-01-21 | 486 | 12.00 | 41.01 | 0.50 | 3.80 | 399.00 | 46.89 | 35.21 | -5.88 | +0.55 | 71 | 3.30 |
| 2027-04-16 | 206 | 9.00 | 5.76 | 0.95 | 1.90 | 144.00 | 16.92 | 29.98 | -11.16 | +0.56 | 1 | 0.95 |
| 2028-01-21 | 486 | 10.00 | 17.51 | 0.65 | 4.70 | 214.00 | 25.15 | 18.89 | -7.64 | +0.63 | 65 | 4.05 |
As of September 23, 2026
Sell covered calls with the data behind you
Find the best ARVN covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→